CoChat

Using the Coronary Artery Calcium Score to Guide Statin Therapy: A Cost-Effectiveness Analysis

Open access
Pletcher, Mark J., Pignone, Michael, Earnshaw, Stephanie, McDade, Cheryl, Phillips, Kathryn A., Auer, Reto, Zablotska, Lydia, Greenland, Philip · 2014 · Circulation: Cardiovascular Quality and Outcomes
Cited by 113

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background—: The coronary artery calcium (CAC) score predicts future coronary heart disease (CHD) events and could be used to guide primary prevention interventions, but CAC measurement has costs and exposes patients to low-dose radiation. Methods and Results—: We estimated the cost-effectiveness of measuring CAC and prescribing statin therapy based on the resulting score under a range of assumptions using an established model enhanced with CAC distribution and risk estimates from the Multi-Ethnic Study of Atherosclerosis. Ten years of statin treatment for 10 000 55-year-old women with high cholesterol (10-year CHD risk, 7.5%) was projected to prevent 32 myocardial infarctions, cause 70 cases of statin-induced myopathy, and add 1108 years to total life expectancy. Measuring CAC and targeting statin treatment to the 2500 women with CAC>0 would provide 45% of the benefit (+501 life-years), but CAC measurement would cost $2.25 million and cause 9 radiation-induced cancers. Treat all was preferable to CAC screening in this scenario and across a broad range of other scenarios (CHD risk, 2.5%–15%) when statin assumptions were favorable ($0.13 per pill and no quality of life penalty). When statin assumptions were less favorable ($1.00 per pill and disutility=0.00384), CAC screening with statin treatment for persons with CAC>0 was cost-effective (<$50 000 per quality-adjusted life-year) in this scenario, in 55-year-old men with CHD risk 7.5%, and in other intermediate risk scenarios (CHD risk, 5%–10%). Our results were critically sensitive to statin cost and disutility and relatively robust to other assumptions. Alternate CAC treatment thresholds (>100 or >300) were generally not cost-effective. Conclusions—: CAC testing in intermediate risk patients can be cost-effective but only if statins are costly or significantly affect quality of life.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circoutcomes.113.000799

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 113

Metadata

Authors
Pletcher, M. J., Pignone, M., Earnshaw, S., McDade, C., Phillips, K. A., Auer, R., Zablotska, L., & Greenland, P.
Venue
Circulation: Cardiovascular Quality and Outcomes
Published
2014-03
Volume
7
Issue
2
Pages
276-284
ISSN
  • 1941-7705 (ISSN-L)
  • 1941-7713
OpenAlex
W2547828902
Cited by
113
References
12
FWCI
11.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Using the Coronary Artery Calcium Score to Guide Statin Therapy: A Cost-Effectiveness Analysis. https://app.cochat.ai/papers/10.1161/circoutcomes.113.000799
The paper
Pletcher, M. J., Pignone, M., Earnshaw, S., McDade, C., Phillips, K. A., Auer, R., Zablotska, L., & Greenland, P. (2014). Using the Coronary Artery Calcium Score to Guide Statin Therapy: A Cost-Effectiveness Analysis. Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/circoutcomes.113.000799

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.